Markets

Pneumonia immunotherapy biotech Aridis Pharmaceuticals sets terms for $28 million IPO

Aridis Pharmaceuticals, which is developing immunotherapies for antibiotic-resistant infections, announced terms for its IPO on Monday.

The San Jose, CA-based company plans to raise $28 million by offering 2.0 million shares at a price range of $13 to $15. Insiders intend to purchase $25 million worth of shares in the offering (89% of the deal). At the midpoint of the proposed range, Aridis Pharmaceuticals would command a fully diluted market value of $111 million.

Aridis Pharmaceuticals was founded in 2003 and booked $1 million in revenue for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol ARDS. Cantor Fitzgerald is the sole bookrunner on the deal. It is expected to price during the week of August 13, 2018.

The article Pneumonia immunotherapy biotech Aridis Pharmaceuticals sets terms for $28 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More